ImmunoGen, Inc. Form 8-K 11-14-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 14, 2005


ImmunoGen, Inc.
(Exact name of registrant as specified in its charter)


 
Massachusetts
0-17999
04-2726691
  
 
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
  


128 Sidney Street, Cambridge, MA 02139
(Address of principal executive offices) (Zip Code)


Registrant's telephone number, including area code: (617) 995-2500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



 


ITEM 8.01 - OTHER EVENTS
 
On November 14, 2005, ImmunoGen, Inc. (Nasdaq: IMGN) issued a press release to announce that ten poster presentations featuring clinical or preclinical findings with the Company’s Tumor-Activated Prodrug (TAP) technology are to be made at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place this week in Philadelphia, PA. Four of these posters will be presented by ImmunoGen researchers and six will be presented by researchers at companies that have licensed certain rights to use ImmunoGen’s TAP technology.

A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.




ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

Exhibit No.
  
Exhibit
     
99.1
  
Press Release of ImmunoGen, Inc. dated November 14, 2005





2
 



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
ImmunoGen, Inc.
 
(Registrant)
   
Date: November 14, 2005
/s/ Karleen M. Oberton
   
 
Karleen M. Oberton
 
Senior Corporate Controller
 
(Principal Accounting Officer)

3